Key takeaways
- Every weight-loss figure from the trials (the 15%, the 20%) comes from the FDA-approved drugs. There is no large trial testing whether compounded versions match them.
- The FDA has documented dosing errors, unapproved salt forms, and adverse events with compounded GLP-1s, and notes that compounded drugs get no premarket review for safety, quality, or effectiveness.
- The price gap that justified compounding is narrowing (brand Wegovy/Zepbound now run roughly $199–499/mo direct from the makers) while the legal window for mass compounding is closing in 2026.
First, what “compounded” really means
A compounded drug is mixed by a pharmacy rather than manufactured and tested by the company that holds the FDA approval. During the 2022–2025 GLP-1 shortages, federal law temporarily allowed pharmacies to compound copies of semaglutide and tirzepatide so patients could get something while the brands were unavailable. That’s why a wave of telehealth companies began selling compounded versions at a fraction of brand prices.
That shortage exception is the key to understanding everything that’s happening now, because the shortages have ended, and with them, the legal basis for most of that compounding.
The evidence gap nobody advertises
Here’s the single most important fact, and it’s easy to miss: all the impressive trial numbers are from the brand-name drugs.
The trials tested Wegovy and Zepbound, not compounds
The 14.9% (semaglutide) and ~15–21% (tirzepatide) average losses come from large randomized trials of the FDA-approved products. There is no comparable trial of compounded semaglutide or tirzepatide head-to-head against the brand. When a compounded provider cites “20% weight loss,” that figure is borrowed from the brand-drug trials. It was not measured on the product you’d receive.
Source: STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SURMOUNT-5 (NEJM 2025)
This doesn’t mean compounded versions don’t work. A well-made compound of the same molecule at the same dose should, in principle, behave similarly. But “should in principle” is doing a lot of work in that sentence, and it’s not the same standard as “tested and verified,” which is what the FDA approval represents.
What the FDA has documented
This is where opinions should give way to the record. The FDA has published specific, named concerns about compounded GLP-1s, not hypotheticals.
Dosing errors, salt forms, and no premarket review
Dosing errors: the FDA has received reports of patients and even clinicians miscalculating doses of compounded semaglutide (in one case, a person self-administered a dose 10 times higher than intended) because of unit-conversion confusion and varying concentrations.
Unapproved salt forms: the FDA has stated that some compounded products used semaglutide sodium or semaglutide acetate, which it considers different active ingredients than the approved drug.
No premarket review: by the FDA’s own description, compounded drugs do not undergo FDA review for safety, quality, or effectiveness before reaching patients: the core thing an approval provides.
Source: FDA, 'FDA's Concerns with Unapproved GLP-1 Drugs' and the FDA compounded-semaglutide dosing-error alert
The straight framing: these are documented risks of the category, not proof that any specific compound is dangerous. A reputable compounding pharmacy using the correct base ingredient, with clear dosing and independent testing, mitigates much of this. The problem is that, as a patient, you often can’t tell which kind you’re dealing with, which is exactly why disclosure matters so much on this route.
Where the law stands in 2026
The legal picture is the part that’s changing fastest, so here’s the current state as of June 2026:
- The shortages are over. Semaglutide came off the FDA shortage list in early 2025; tirzepatide’s resolved before it. That removed the main legal basis for large-scale compounding.
- The FDA is moving to close the bulk door. On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding “no clinical need” for outsourcing facilities to compound them from bulk ingredient. Public comment is open through June 29, 2026, and analysts expect the exclusion to be finalized later in the year.
- A narrow lane may remain. Patient-specific compounding by a pharmacy (the 503A pathway) can still apply in genuine individual cases, for example, a documented allergy to an inactive ingredient in the brand. But the era of mass-marketed compounded GLP-1 as a cheaper default is closing.
Translation: if you’re choosing a route in 2026, the compounded option is not just an evidence question: it’s one with a shrinking and uncertain legal footing.
The price gap is closing too
The whole appeal of compounded GLP-1 was cost. But that math has shifted: the manufacturers now sell the brand drugs directly at far lower cash prices than the old list prices.
Brand, direct, is now far cheaper than it was
Self-pay brand Wegovy and Zepbound now run roughly $199–499/month direct from the makers, and may be lower with insurance. Compounded products are often $150–300/month all-in. The gap is real but no longer dramatic, and you’re weighing it against an FDA-tested product versus one that isn’t.
Source: Manufacturer direct programs (NovoCare for Wegovy; LillyDirect for Zepbound), pricing as of mid-2026
So which should you choose?
That’s a decision for you and a clinician, but the evidence points to a clear default and a narrow exception:
- The FDA-approved brand is the evidence-backed, lower-risk route. It’s what the trials measured, it’s FDA-tested, and it’s no longer dramatically more expensive. For most people, this is the recommendation.
- If you’re going compounded anyway (because of cost, a genuine clinical reason, or personal choice) the most protective thing you can do is pick a provider that discloses what matters: a named dispensing pharmacy, a lawful basis, independent testing, and clean billing.
Frequently asked questions
Is compounded semaglutide as effective as Wegovy?
There’s no large trial answering that directly. All the efficacy data is from the FDA-approved drugs. A correctly made compound of the same molecule at the same dose should behave similarly in principle, but “should in principle” is not the same as “tested and verified.”
Is compounded GLP-1 illegal now?
It’s not blanket-illegal, but the legal basis narrowed sharply once the shortages ended, and the FDA is moving in 2026 to bar outsourcing facilities from compounding it from bulk ingredient. Patient-specific compounding for genuine individual reasons may still apply. The situation is changing fast, so verify the current state before relying on it.
Why is compounded cheaper if it's the same drug?
It skips the FDA approval process, large-scale manufacturing standards, and brand pricing. That lower cost is also the trade-off: no premarket review for safety, quality, or effectiveness. And with manufacturer-direct brand prices now around $199–499/month, the savings are smaller than they were.
What's the safest way to get a GLP-1?
The FDA-approved brand, prescribed and monitored by a licensed clinician, is the most evidence-backed and lowest-risk route. If cost is the barrier, an insurance appeal or a manufacturer-direct program is usually a better first move than switching to a compounded product. See our free appeal templates and price comparison.
- Trial efficacy data is from the FDA-approved drugs only: STEP 1 (semaglutide), NEJM 2021 (NEJMoa2032183); SURMOUNT-1 (tirzepatide), NEJM 2022 (NEJMoa2206038); SURMOUNT-5 (head-to-head), NEJM 2025 (NEJMoa2416394). There is no large randomized trial of compounded semaglutide or tirzepatide against the brand-name products.
- FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss: compounded drugs do not undergo FDA premarket review for safety, quality, or effectiveness: fda.gov
- FDA, FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (reports include a patient who self-administered a dose 10× higher than intended): fda.gov
- FDA on salt forms: semaglutide sodium and semaglutide acetate are different active ingredients than the approved drug; FDA wrote to the National Association of Boards of Pharmacy expressing this concern on April 27, 2023.
- FDA, FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (announced April 30, 2026; Federal Register 2026-08552, published May 1, 2026; public comment open through June 29, 2026): fda.gov
This article was produced using our 31-point scoring methodology; every primary source we cite across the site is collected in our consolidated bibliography. We analyze published research and consumer reviews; we do not personally test medical products. This is not medical advice. Consult a licensed clinician.